



## Transforming the treatment of Asia prevalent cancers



- Focus on Asia-prevalent tumours**  
eg Gastric, biliary tract, liver
- Proprietary pipeline of 5 drugs**  
Lead in pivotal studies
- Strong cash position**  
USD 66M raised in the last year and over USD 10M revenues
- Partnerships with world-leading pharma and biotechs**  
Including BMS, CSL, Ammirall
- Led by clinical development veterans**  
With global pharma experience

**Varlitinib (ASLAN001)** is a novel agent that has shown strong efficacy in a variety of difficult-to-treat tumour types. Varlitinib has completed phase 2 studies in gastric and breast cancer, and is entering pivotal studies for BTC. *Varlitinib* has received Orphan Drug Designation from the US FDA for cholangiocarcinoma and gastric cancer, and from the Korea FDA for biliary tract cancer (BTC).

**ASLAN002** is a highly potent cMET and RON inhibitor, an immune checkpoint inhibitor. In August 2016, BMS acquired the global rights to ASLAN002.

**ASLAN003** is a novel DHODH inhibitor which has shown to be a potent inducer of p53, and is being investigated in solid tumours and acute myeloid leukaemia (AML).

**ASLAN004** is a monoclonal IL4/IL13 antibody targeting asthma and certain tumour types.

**ASLAN005** is a monoclonal antibody targeted against RON, an immune checkpoint inhibitor.

**Modybodies** are a novel type of antibody fragments which can be linked together into heterodimers/trimers to inhibit multiple targets.

Program	Target	Indication	Disc	PC	Ph 1	Ph 2	Pivotal	Originator
Varlitinib/ ASLAN001	panHER Growth pathway inhibitor	BTC Gastric cancer Breast cancer Colorectal cancer	██████████	██████████	██████████	██████████	██████████	ARRAY
ASLAN002	MET/RON Immune checkpoint inhibitor	Solid tumours	██████████	██████████	██████████	██████████	BMS acquired global rights in 2016	Bristol-Myers Squibb
ASLAN003	DHODH Metabolic stress inducer via p53	AML, Solid tumours	██████████	██████████	██████████	██████████	██████████	Ammirall
ASLAN004	IL4/13 Macrophage anti-tumour enhancer	Asthma, Solid tumours	██████████	██████████	██████████	██████████	██████████	CSL
ASLAN005	RON Immune checkpoint inhibitor	Solid tumours	██████████	██████████	██████████	██████████	██████████	Agency for Science, Technology and Research
Modybodies	mAb fragments Targets not disclosed	Oncology	██████████	██████████	██████████	██████████	██████████	NANYANG TECHNOLOGICAL UNIVERSITY

Proprietary Portfolio\*

### PARTNERS

Partnerships with leading global pharma and international biotech companies:



### INVESTORS

ASLAN has raised over 3 billion NTD to date. We are supported by leading healthcare investors and the Singapore government:



### UNDERWRITER AND AUDITOR



### SERVICE PARTNERS





## DEVELOPING IN ASIA FOR GLOBAL MARKETS

- Focus on Asia prevalent tumour types
- We run studies across Asia, where patient numbers are high
- Data is leveraged for approvals in US, EU and other global markets where often these are orphan diseases and accelerated approval is possible
- Few – if any – approved therapies for these indications such as gastric cancer, colorectal cancer and biliary tract cancer.



## EXPERIENCED MANAGEMENT

<b>Dr Carl Firth</b> <b>CEO</b>	<ul style="list-style-type: none"> <li>• Formerly Head of Asia Healthcare Investment Banking, Merrill Lynch</li> <li>• 16 years in pharmaceutical industry, including roles in Asia and China leading new product development</li> </ul>
<b>Dr Bertil Lindmark</b> <b>CMO</b>	<ul style="list-style-type: none"> <li>• Former CSO, Global Head of R&amp;D and Exec Director at Almirall, leading team of 550 across 3 sites, responsible for 4 major market approvals in US / EU</li> <li>• Previously served as Head of Clin Dev, AstraZeneca</li> </ul>
<b>Dr Mark McHale</b> <b>COO</b>	<ul style="list-style-type: none"> <li>• Former Head of Molecular Sciences at AstraZeneca Respiratory &amp; Inflammation</li> <li>• Over 25 years pharmaceutical R&amp;D experience</li> </ul>
<b>Jeff Tomlinson</b> <b>CBO</b>	<ul style="list-style-type: none"> <li>• 12 years senior BD and IP experience at North American biotech companies and VC</li> <li>• 5 years pharmaceuticals R&amp;D</li> </ul>
<b>Ben Goodger</b> <b>General Counsel</b>	<ul style="list-style-type: none"> <li>• Previously Head of IP Licensing and Transactions at Osborne Clarke</li> <li>• 20 years of experience in IP and licensing</li> </ul>
<b>Christine Wang</b> <b>IR Director</b>	<ul style="list-style-type: none"> <li>• Over 10 years' experience in Asia and US equity markets</li> <li>• Extensive industry knowledge in global high-tech and biotech fields</li> </ul>
<b>Prof Sir David Lane</b> <b>Chair of Scientific Advisory Board</b>	<ul style="list-style-type: none"> <li>• Discoverer of p53 in 1979</li> <li>• Chief Scientist, A*STAR, Director of Ludwig Institute</li> <li>• Previously Chief Scientist, Cancer Research UK</li> </ul>

## CONTACT

### SINGAPORE

83 Clemenceau Avenue  
#12-03 UE Square  
Singapore 239920  
+65 6222 4235

### TAIWAN

32F International Trade Building  
333 Keelung Road Sec 1  
Taipei 11012  
+886 2757 6700

### CHINA

1206 Chong Hing Finance Center  
288 Nanjing Road West, Huangpu District  
Shanghai 200003  
+86 21 6133 7950

### AUSTRALIA

58 Gipps Street,  
Collingwood  
Victoria, 3066

[www.aslanpharma.com](http://www.aslanpharma.com)

[investor@aslanpharma.com](mailto:investor@aslanpharma.com)

## OUR AWARDS

- Asian Biotech of the Year 2016 (BioPharma Asia)
- Executive of the Year (BioPharma Asia finalist)
- Best Company in Emerging Market (Scrip finalist)
- Most Promising Company of the Year (ChinaBio)
- Small Business Rising Star (British Chamber)
- Young Professional (British Chamber finalist)
- Best Company in Emerging Market (Scrip finalist)
- Best Management Team (Scrip finalist)
- Awarded Red Herring Top 100 (Asia)
- Finalist for Red Herring Top 100 (Global)
- Top 100 Scrip Leader

**SCRIP**

British  
Chamber of Commerce

CHINABIO®

BioPharma  
ASIA

RED  
HERRING  
100  
WINNER  
ASIA